Prof Chris Semsarian
MB BS PhD FRACP FAHA FCSANZ

  • Head, Molecular Cardiology Program, Centenary Institute, Sydney
  • Cardiologist, Royal Prince Alfred Hospital, Sydney
  • Professor, Faculty of Medicine, University of Sydney
  • NHMRC Practitioner Fellow
  • Assistant Director, Centenary Institute
  • Professor Chris Semsarian is a cardiologist with a specific research focus in the genetic basis of cardiovascular disease.

    Prof Semsarian trained at the University of Sydney, Royal Prince Alfred Hospital, and Harvard Medical School.

    A focus area of his research is in the investigation and prevention of sudden cardiac death in the young, particularly amongst children and young adults. Prof Semsarian has an established research program which is at the interface of basic science and clinical research, with the ultimate goal to prevent the complications of genetic heart diseases in our community.

    Prof Semsarian is the director of two speciality clinics at RPAH: the Genetic Heart Disease and Hypertrophic Cardiomyopathy Clinics. 

    To arrange a consultation, please contact the Royal Prince Alfred Hospital on 9516 6111.

  • The investigation and prevention of sudden cardiac death in the young, particularly amongst children and young adults

  • Selected publications:

    Semsarian C, Wu MJ, Ju YK, Marciniec T, Yeoh T, Allen DG, Harvey RP, Graham RM. Skeletal muscle hypertrophy is mediated by a Ca2+ dependent calcineurin signalling pathway. Nature. 1999; 400: 576-581.


    Semsarian C, Giewat M, Georgakopoulos D, et al.  The L-type calcium-channel inhibitor diltiazem prevents cardiomyopathy in a mouse model.  J. Clin. Invest. 2002; 109: 1013-20.


    Ingles J, Doolan A, Chiu C, Seidman JG, Seidman CE, Semsarian C. Compound and double mutations in hypertrophic cardiomyopathy patients: implications for genetic testing and counselling. J. Med. Genet. 2005; 42: e59.


    Maron BJ, SpiritoP, Shen WK, …, Semsarian C, Bruzzi P. Prevention of sudden cardiac death and selection of patients for implantable cardioverter-defibrillators in hypertrophic cardiomyopathy. J.A.M.A. 2007; 298: 405-12.


    Tsoutsman T, Kelly M, Ng D, Tan J, Tu E, Lam L, Bogoyevitch M, Seidman CE, Seidman JG, Semsarian C. Severe heart failure and early mortality in a double mutation mouse model of familial hypertrophic cardiomyopathy. Circulation. 2008; 117: 1820-31.


    Kelly M, Semsarian C. Multiple mutations in genetic cardiovascular disease: a marker of disease severity? Circ. Cardiovasc. Genet. 2009; 2: 182-190.


    Wilcox I, Semsarian C. Obstructive Sleep Apnea: A Respiratory Syndrome With Protean Cardiovascular Manifestations. J Am Coll Cardiol. 2009; 54: 1810-1812


    Chiu C, Bagnall RD, Ingles J, Yeates L, Kennerson M, Donald JA, Jormakka M, Lind JM, Semsarian C. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. J Am Coll Cardiol. 2010; 55: 1127-35.


    Gray B, Ingles J, Semsarian C. Natural History of Genotype Positive Phenotype Negative Patients with Hypertrophic Cardiomyopathy. Int J Cardiol. 2011; 152: 258-9.


    Semsarian C. Guidelines for the diagnosis and management of hypertrophic cardiomyopathy. Heart Lung Circulation. 2011; 20: 688-90.